Results 31 to 40 of about 70,790 (271)

Inflammatory cascades driven by tumor necrosis factor-alpha play a major role in the progression of acute liver failure and its neurological complications. [PDF]

PLoS ONE, 2012
Acute liver failure (ALF) due to ischemic or toxic liver injury is a clinical condition that results from massive loss of hepatocytes and may lead to hepatic encephalopathy (HE), a serious neuropsychiatric complication.
Anne Chastre, Mireille Bélanger, Elizabeth Beauchesne, Bich N Nguyen, Paul Desjardins, Roger F Butterworth   +5 more
doaj   +1 more source

Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept

Pediatric Rheumatology Online Journal, 2021
Background Alterations in the composition of the fecal microbiota in children with juvenile idiopathic arthritis (JIA) have been observed in several studies, but it has not been determined whether the standard treatment for JIA changes the composition or
Anders Öman, Johan Dicksved, Lars Engstrand, Lillemor Berntson   +3 more
doaj   +1 more source

Etanercept protects ovarian reserve against ischemia/reperfusion injury in a rat model

Archives of medical science : AMS, 2019
Introduction Etanercept has been widely used in autoimmune diseases for blocking tumor necrosis factor α (TNF-α), which is an inflammatory cytokine. The anti-apoptotic and anti-inflammatory effects of etanercept against ischemia/reperfusion (I/R) injury ...
Meryem Eken, G. S. Ersoy, E. Kaygusuz, B. Devranoğlu, M. Takir, Ö. Çilingir, Ö. Çevik   +6 more
semanticscholar   +1 more source

Evaluation of Efficacy and Safety of Etanercept and Etanercept + Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis without Systemic Manifestations

Вопросы современной педиатрии, 2016
Background: At present, it is urgent to find ways to overcome the inefficiency of and intolerance to the methotrexate therapy in patients with juvenile idiopathic arthritis (JIA).
T. M. Bzarova, Ye. I. Alekseeva, S. I. Valieva, R. V. Denisova, K. B. Isaeva, Ye. G. Chistyakova, A. M. Chomakhidze, T. V. Sleptsova, A. N. Fetisova, O. L. Lomakina, M. A. Soloshenko   +10 more
doaj   +1 more source

Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy

Journal of Neuroinflammation, 2021
Background Tumor necrosis factor-α (TNF-α) plays a central role in Alzheimer’s disease (AD) pathology, making biologic TNF-α inhibitors (TNFIs), including etanercept, viable therapeutics for AD.
Weijun Ou, Joshua Yang, Juste Simanauskaite, Matthew Choi, Demi M. Castellanos, Rudy Chang, Jiahong Sun, Nataraj Jagadeesan, Karen D. Parfitt, David H. Cribbs, Rachita K. Sumbria   +10 more
doaj   +1 more source

A randomized controlled trial of etanercept in the treatment of refractory recurrent spontaneous abortion with innate immune disorders

Taiwanese Journal of Obstetrics & Gynecology, 2019
Objective: To evaluate the effectiveness of etanercept in the treatment of refractory recurrent spontaneous abortion with innate immune disorders. Materials and methods: A randomized controlled trial in patients with refractory innate immune RSA was ...
Jinhua Fu, Lin Li, Lijuan Qi, Long Zhao
doaj   +1 more source

Etanercept therapy in rheumatoid arthritis: Efficacy and safety [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2013
Introduction. Etanercept, tumor necrosis factor (TNFα) antagonist, lowers the disease activity level in patients with rheumatoid arthritis (RA), reduces joint destruction saving physical functions and improving life quality. Objective. The aim of this
Ilić Tatjana, Milić Biljana, Ćelić Dejan, Vučković Biljana, Mitić Igor   +4 more
doaj   +1 more source

Effectiveness and safety of baricitinib for juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis

Arthritis Care &Research, Accepted Article.
Objectives Evaluate the efficacy and safety of baricitinib in paediatric patients with active JIA‐U or chronic anterior ANA‐positive uveitis, who had an inadequate response to MTX or bDMARDs. Methods JUVE‐BRIGHT was an open‐label, active‐controlled, Phase‐3 multicentre trial which utilized a novel design, including 1:1 randomization to an active ...
Athimalaipet V. Ramanan, Catherine M. Guly, Gabriele Simonini, Stuart Keller, Priyanka Sen, Thorsten Holzkaemper, Joana Araújo, Pierre Quartier   +7 more
wiley   +1 more source

Sex differences in medication discontinuation in axial spondyloarthritis.

Arthritis Care &Research, Accepted Article.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or Janus kinase inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we ...
Rachael Stovall, Cinthia Blat, Eric Roberts, Jean W. Liew, Katherine Wysham, Namrata Singh, Janna Friedly, Lianne S. Gensler, Gabriela Schmajuk, Jinoos Yazdany   +9 more
wiley   +1 more source

Increased Anti‐Psoriatic Effect of Anti‐Inflammatory Dendrimers Using Fluid Catanionic Vesicle‐Based Topical Formulations

Advanced Healthcare Materials, EarlyView.
Next‐Generation Psoriasis Therapy – With advanced dendrimer‐based formulations, this study paves the way for highly effective, skin‐permeable treatments. Encapsulated in fluid catanionic vesicles, IMD‐006 and its analogues show promising anti‐psoriatic effects offering a targeted, non‐invasive approach to managing chronic skin inflammation.
Ranime Jebbawi, Abdelouahd Oukhrib, Emily Clement, Hélène Labie, Stéphanie Cassel, Séverine Fruchon, Anne‐Marie Caminade, Michel Simon, Rémy Poupot, Cédric‐Olivier Turrin, Muriel Blanzat   +10 more
wiley   +1 more source